AI analyzes CT scans to find safer radiation levels for liver cancer patients
NCT ID NCT07346573
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study used artificial intelligence to examine CT scans from 274 liver cancer patients who had already received radiation therapy. The goal was to find the radiation dose that causes a visible liver reaction, which could help doctors avoid liver injury in future treatments. Researchers compared patients who developed this reaction with those who did not, looking at scan features and clinical information. Since this was a retrospective study, no new treatments or procedures were given to participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors set safer radiation doses for liver cancer treatment, reducing the risk of liver injury.
What could go wrong
This is a retrospective observational study, so it can show patterns but cannot prove cause and effect. The findings may not apply to all patients or treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Third Xiangya Hospital
Changsha, Hunan, China